Voss-affiliated funds report RNTX share purchases near $1.37
Rhea-AI Filing Summary
Rein Therapeutics (RNTX): Voss Capital–affiliated entities reported open‑market purchases of common stock. On 10/24/2025, Voss Value Master Fund, L.P. bought 30,176 shares at $1.3904, bringing its beneficially owned balance to 729,616 shares. On 10/27/2025, the fund bought 92,642 shares at $1.37, for a new total of 822,258 shares.
Voss Value‑Oriented Special Situations Fund, L.P. bought 4,840 shares at $1.3687 on 10/27/2025, increasing to 321,608 shares, and 178,392 shares at $1.39 on 10/28/2025, increasing to 500,000 shares. The holdings are reported as indirect through the respective funds. The reporting persons state they are members of a group that collectively beneficially owns over 10% of the outstanding common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 306,050 shares
Net Buy
4 txns
Insider
Voss Capital, LP, Voss Value Master Fund, LP, Voss Value-Oriented Special Situations Fund, LP, Voss Advisors GP, LLC, Cocke Travis W.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
306,050 shs ($423K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, $0.001 par value | 178,392 | $1.39 | $248K |
| Purchase | Common Stock, $0.001 par value | 92,642 | $1.37 | $127K |
| Purchase | Common Stock, $0.001 par value | 4,840 | $1.3687 | $7K |
| Purchase | Common Stock, $0.001 par value | 30,176 | $1.3904 | $42K |
Holdings After Transaction:
Common Stock, $0.001 par value — 822,258 shares (Indirect, By: Voss Value Master Fund, L.P.);
Common Stock, $0.001 par value — 500,000 shares (Indirect, By: Voss Value-Oriented Special Situations Fund, L.P.)
Footnotes (5)
- F1. This Form 4 is filed jointly by Voss Value Master Fund, LP ("Voss Value Master Fund"), Voss Value-Oriented Special Situations Fund, LP ("Voss Value-Oriented Special Situations Fund"), Voss Advisors GP, LLC ("Voss GP"), Voss Capital, LP ("Voss Capital") and Travis W. Cocke (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, that collectively beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F2. Securities owned directly by Voss Value Master Fund. Voss GP, as the general partner of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Voss Capital, as the investment manager of Voss Value Master Fund, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value Master Fund.
- F3. Securities owned directly by Voss Value-Oriented Special Situations Fund. Voss GP, as the general partner of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Voss Capital, as the investment manager of Voss Value-Oriented Special Situations Fund, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund. Mr. Cocke, as the managing member of Voss Capital and Voss GP, may be deemed to beneficially own the securities owned directly by Voss Value-Oriented Special Situations Fund.
- F4. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3300 to $1.4000, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F5. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.3600 to $1.3700, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Voss-affiliated funds report in the RNTX Form 4?
They reported open‑market purchases of Rein Therapeutics common stock across four transactions between 10/24/2025 and 10/28/2025.
What were Voss Value Master Fund’s holdings after the reported trades?
Beneficially owned shares increased to 729,616 after 10/24/2025 and to 822,258 after 10/27/2025.
What did Voss Value‑Oriented Special Situations Fund report buying?
It bought 4,840 shares at $1.3687 on 10/27/2025 and 178,392 shares at $1.39 on 10/28/2025.
What were the Special Situations Fund’s holdings after its trades?
Beneficially owned shares increased to 321,608 after 10/27/2025 and to 500,000 after 10/28/2025.
Are these holdings reported as direct or indirect ownership?
They are reported as indirect ownership through the respective Voss funds, as stated in the filing.
Do the reporting persons claim over 10% beneficial ownership of RNTX?
They state they are members of a group that collectively beneficially owns over 10% of the outstanding common stock.